<DOC>
	<DOCNO>NCT00090493</DOCNO>
	<brief_summary>The hope peptide vaccine stimulate immune system attack kill myeloma cell . The purpose generate anti-myeloma T-cells kill myeloma cell nothing else .</brief_summary>
	<brief_title>Study MAGE-A3 NY-ESO-1 Immunotherapy Combo With DTPACE Chemo Auto Transplantation Multiple Myeloma</brief_title>
	<detailed_description>This experimental treatment consist receive peptide vaccination shoot skin ( subcutaneous ) . We choose vaccinate peptide derive cancer protein find myeloma cancer . The purpose generate anti-myeloma T-cells kill myeloma cell nothing else . The peptides fragment two tumor protein call MAGE-A3 NY-ESO-1 . In order eligible study myeloma cell must express either MAGE-A3 NY-ESO-1 , myeloma must severe enough require chemotherapy stem cell transplantation . You must also appropriate HLA tissue type . Patients MAGE-A3 positive myeloma HLA-A*0101 -B*35 positive receive MAGE-A3 peptide vaccine . Patients NY-ESO-1 positive myeloma HLA-A*0201 receive NY-ESO-1 peptide vaccine . Three injection 300µg per injection ( 1.5mls ) peptide give subcutaneously together adjuvant GM-CSF 500µg ( site 0.5 ml ) two-week interval . Your myeloma cell , obtain routine bone marrow aspirate , test laboratory presence MAGE-A3 and/or NY-ESO-1 protein . HLA tissue type determine standard method Clinical Laboratory . This allow allocation correct vaccine individual patient . Prior start 6-day course chemotherapy call DTPACE , white blood cell collect procedure call leukapheresis ( leukapheresis no.1 ) . Your white blood cell frozen duration chemotherapy order protect white blood cell harmful effect chemotherapy . After chemotherapy give , stem cell collect leukapheresis ( PBSC collection ) store time transplantation . After short period rest , white blood cell leukapheresis no.1 thaw re-infused . This ensure white blood cell best possible condition respond peptide vaccine . A set three vaccination peptide two-week interval follow . The hope vaccination generate precious anti-myeloma white blood cell . You undergo leukapheresis ( leukapheresis no.2 ) collect anti-myeloma white blood cell , frozen order protect precious cell chemotherapy drug infuse single double auto-transplant . A single dose Melphalan precede transplant . The stem cell collect DTPACE give transplant . For receive two transplant , regimen thalidomide dexamethasone give approximately 10 week two transplant . You stop thalidomide 28 day second transplant . After completion transplant , anti-myeloma white blood cell collect leukapheresis . 2 thaw re-infused . These anti-myeloma cell boost three peptide vaccination two-week interval . Finally , complete three vaccination undergo another leukapheresis ( . 3 ) . The anti-myeloma white blood cell collect leukapheresis . 3 frozen store possible future use . Six final vaccine give monthly interval amplify anti-myeloma white blood cell .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>MM patient active , symptomatic myeloma , meet criterion thus establish presence highrisk myeloma MM SalmonDurie Stage : IA &amp; B ( abnormal cytogenetics* ) , IIA , IIB , IIIA , IIIB , meet criterion thus establish presence highrisk myeloma MM must meet one follow criterion : ) Patients MAGEA3 positive MM tissue type HLAA*0101 , * B35 , allocate receive MAGEA3168176 peptide vaccine . b ) Patients NYESO1 positive MM tissue type HLAA*0201 allocate NYESO1156C165V peptide vaccine . c ) Patients NYESO1 positive MAGEA3 negative positive MM tissue type HLAA*0101 , * B35 HLAA*0201 , receive vaccination NYESO1156C165V peptide vaccine . ) Patients NYESO1 negative MAGEA3 positive MM tissue type HLAA*0101 , * B35 HLAA*0201 , receive vaccination MAGEA3 peptide vaccine . Karnofsky performance score ≥=70 , unless bone pain cause MM result Karnofsky score &gt; =50 . Age 1870 year old Hb &gt; =8.0gm/dl , ANC &gt; =1,000/microliters , platelet count &gt; = 100,000/microliters . Patients must sign IRBapproved consent form inform investigational nature study Negative serology HIV , Hepatitis C negative Hepatitis B surface antigen . CD4+ count &gt; 400/microliters Life expectancy &gt; 6 month Negative pregnancy test female agree two form contraception abstinence . Provisional insurance approval single double autotransplant ( ) MGUS , indolent smolder myeloma Chemotherapy immunosuppressive treatment e.g . glucocorticosteroids , cyclophosphamide , methotrexate within 4 week prior enrollment Patients malignancies carcinomainsitu cervix nonmelanomatous skin cancer Fever active infection Liver function : total bilirubin &gt; 2.5xULN AST/ALT &gt; 2.5xULN Renal function : patient dialysis , serum creatinine &gt; 2.0mg/dl Simultaneous treatment second investigational drug biologic agent MM Other intercurrent serious illness , e.g . cardiac , pulmonary , hepatic disease , uncontrolled diabetes , etc Cardiac : Patients recent ( &lt; =6 month ) myocardial infarction , unstable angina , difficult control congestive heart failure , uncontrolled hypertension , difficult control cardiac arrythmias ineligible . Ejection fraction ECHO must &gt; = 50 % must perform within 60 day prior registration , unless patient receive chemotherapy within period time ( dexamethasone thalidomide exclude ) , case LVEF must repeat Pulmonary : Patients must history chronic obstructive chronic restrictive pulmonary disease result unacceptable lung function : patient must adequate pulmonary function study &gt; = 50 % predict mechanical aspect ( FEV1 , FVC , etc ) diffusion capacity ( DLCO ) &gt; = 50 % predict . Patients unable complete pulmonary function test due myeloma related pain fracture must high resolution CT scan chest must also acceptable arterial blood gas define P02 great 70 Patients must able receive full dos DT PACE , opinion treat investigator , exception : A ) Patients receive prior adriamycin &gt; 450 mg/m2 LVEF &lt; 55 % . Adriamycin omit patient . B ) Patients creatinine clearance 30 50 ml/minute , receive 50 % cisplatin dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Mage-A3</keyword>
	<keyword>Transplant</keyword>
	<keyword>Peptide</keyword>
	<keyword>DTPACE</keyword>
	<keyword>vaccine</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>NY-ESO-1</keyword>
</DOC>